Trial intelligence / Profile preview

Systemic drugs for severe recurrent aphthous stomatitis

ACTRN12608000372381Phase 4Active, not recruiting

Sponsor
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Start
Feb 2004
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label trial of thalidomide, pentoxifylline, colchicine and dapsone in aphthosis (RAS) (4 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoint: Reduction of recurrent aphthous stomatitis bouts. Started Feb 2004; status: active, not recruiting.

02

Drugs

thalidomidepentoxifyllinecolchicinedapsone
03

Conditions

aphthosis (RAS)

Beyond the preview

Go deeper on ACTRN12608000372381.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12608000372381.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call